Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes (NCT06239506) | Clinical Trial Compass
UnknownNot Applicable
Novel Brominated and Organophosphate Flame Retardants and Type 2 Diabetes
China340 participantsStarted 2022-01-01
Plain-language summary
As alternative flame retardants (FRs), novel brominated flame retardants (NBFRs) and organophosphate flame retardants (OPFRs) are ubiquitous in environment and may cause endocrine disruption effects. The associations between traditional endocrine-disrupting chemicals (EDCs) and type 2 diabetes have been extensively reported in epidemiological studies. To date, however, human-based evidence on the effects of NBFRs and OPFRs is lacking. The investigators conducted a case-control study of 344 participants aged 25-80 years from Shandong Province, East China, to assess potential associations between serum NBFR and OPFR concentrations and etiology of type 2 diabetes for the first time.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. age 18 \~ 75 years old;
✓. type 2 diabetes patients diagnosed in the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) , HBA1C ≥7.0% and \<10.5% ;
✓. patients signed informed consent.
✓. age 18 \~ 75 years old;
✓. healthy population recruited from the First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province) ;
✓. living in the monitoring area for more than 6 months within 12 months;
✓. normal thyroid function and no history of thyroid cancer were needed in the control group;
✓. Fasting Blood Glucose level of 0.7 mmol/l was needed in the Control Group of Type 2 diabetes Mellitus Without History of diabetes;
Exclusion criteria
✕. pregnant, lactating women, patients with acute cardiac cerebrovascular disease;